Why the study?
Does continuous infusion or weekly scheduling of doxorubicin reduce cardiotoxicity compared to a standard three-weekly schedule in patients receiving doxorubicin therapy?
Does continuous infusion or weekly scheduling of doxorubicin reduce cardiotoxicity compared to a standard three-weekly schedule in patients receiving doxorubicin therapy?
Altering doxorubicin dosing to a weekly or continuous infusion schedule reduces cardiotoxicity and allows for higher cumulative doses without compromising therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Supports considering weekly doxorubicin to limit cardiotoxicity; leaves open validation in prospective trials with contemporary regimens.
Lum et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: